Juanita M Crook1, Peixin Zhang2, Thomas M Pisansky3, Edouard J Trabulsi4, Mahul B Amin5, William Bice6, Gerard Morton7, Nadeem Pervez8, Eric Vigneault9, Charles Catton10, Jeff Michalski11, Mack Roach12, David Beyer13, Ashesh Jani14, Eric Horwitz15, Viroon Donavanik16, Howard Sandler5. 1. BC Cancer Agency and University of British Columbia, Kelowna, British Columbia, Canada. Electronic address: jcrook@bccancer.bc.ca. 2. NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, Pennsylvania. 3. Mayo Clinic, Rochester, Minnesota. 4. Jefferson University, Philadelphia, Pennsylvania. 5. Cedars-Sinai Medical Center, Los Angeles, California. 6. John Muir Health Systems, Walnut Creek, California. 7. Odette Cancer Center/University of Toronto, Toronto, Ontario, Canada. 8. Cross Cancer Institute, Edmonton, Alberta, Canada. 9. CHU de Québec Université Laval, Quebec, Canada. 10. University Health Network/University of Toronto, Toronto, Ontario, Canada. 11. Washington University, St Louis, Missouri. 12. University of California, San Francisco, San Francisco, California. 13. Arizona Oncology Services Foundation, Sedona, Arizona. 14. Emory University, Atlanta, Georgia. 15. Fox Chase Cancer Center, Philadelphia, Pennsylvania. 16. Christiana Care, Newark, Delaware.
Abstract
PURPOSE: Only retrospective data are available for low-dose-rate (LDR) salvage prostate brachytherapy for local recurrence after external beam radiation therapy (EBRT). The primary objective of this prospective phase 2 trial (NCT00450411) was to evaluate late gastrointestinal and genitourinary adverse events (AEs) after salvage LDR brachytherapy. METHODS AND MATERIALS: Eligible patients had low- or intermediate-risk prostate cancer before EBRT and biopsy-proven recurrence >30 months after EBRT, with prostate-specific antigen levels <10 ng/mL and no regional/distant disease. The primary endpoint was grade 3 or higher late treatment-related gastrointestinal or genitourinary AEs occurring 9 to 24 months after brachytherapy. These AEs were projected to be ≤10%, with ≥20% considered unacceptable. All events were graded with National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Multivariate analyses investigated associations of pretreatment or treatment variables with AEs. RESULTS: One hundred patients from 20 centers were registered from May 2007 to January 2014. The 92 analyzable patients had a median follow-up of 54 months (range, 4-97) and a median age of 70 years (interquartile range [IQR], 65-74). The initial Gleason score was 7 in 48% of patients. The median dose of EBRT was 74 Gy (IQR, 70-76) at a median interval of 85 months previously (IQR, 60-119). Only 16% had androgen deprivation at study entry. Twelve patients (14%) had late grade 3 gastrointestinal/genitourinary AEs, with no treatment-related grade 4 or 5 AEs. No pretreatment variable predicted late AEs, including prior EBRT dose and elapsed interval. Higher V100 (percentage of prostate enclosed by prescription isodose) predicted both occurrence of late AEs (odds ratio, 1.24; 95% confidence interval, 1.02-1.52; P = .03) and earlier time to first occurrence (hazard ratio, 1.18; 95% CI, 1.03-1.34; P = .02). CONCLUSIONS: This prospective multicenter trial reports outcomes of salvage LDR brachytherapy for post-EBRT recurrence. The rate of late grade 3 AEs did not exceed the unacceptable threshold. The only factor predictive of late AEs was implant dosimetry reflected by V100. Efficacy outcomes will be reported at a minimum of 5-year follow-up.
PURPOSE: Only retrospective data are available for low-dose-rate (LDR) salvage prostate brachytherapy for local recurrence after external beam radiation therapy (EBRT). The primary objective of this prospective phase 2 trial (NCT00450411) was to evaluate late gastrointestinal and genitourinary adverse events (AEs) after salvage LDR brachytherapy. METHODS AND MATERIALS: Eligible patients had low- or intermediate-risk prostate cancer before EBRT and biopsy-proven recurrence >30 months after EBRT, with prostate-specific antigen levels <10 ng/mL and no regional/distant disease. The primary endpoint was grade 3 or higher late treatment-related gastrointestinal or genitourinary AEs occurring 9 to 24 months after brachytherapy. These AEs were projected to be ≤10%, with ≥20% considered unacceptable. All events were graded with National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Multivariate analyses investigated associations of pretreatment or treatment variables with AEs. RESULTS: One hundred patients from 20 centers were registered from May 2007 to January 2014. The 92 analyzable patients had a median follow-up of 54 months (range, 4-97) and a median age of 70 years (interquartile range [IQR], 65-74). The initial Gleason score was 7 in 48% of patients. The median dose of EBRT was 74 Gy (IQR, 70-76) at a median interval of 85 months previously (IQR, 60-119). Only 16% had androgen deprivation at study entry. Twelve patients (14%) had late grade 3 gastrointestinal/genitourinary AEs, with no treatment-related grade 4 or 5 AEs. No pretreatment variable predicted late AEs, including prior EBRT dose and elapsed interval. Higher V100 (percentage of prostate enclosed by prescription isodose) predicted both occurrence of late AEs (odds ratio, 1.24; 95% confidence interval, 1.02-1.52; P = .03) and earlier time to first occurrence (hazard ratio, 1.18; 95% CI, 1.03-1.34; P = .02). CONCLUSIONS: This prospective multicenter trial reports outcomes of salvage LDR brachytherapy for post-EBRT recurrence. The rate of late grade 3 AEs did not exceed the unacceptable threshold. The only factor predictive of late AEs was implant dosimetry reflected by V100. Efficacy outcomes will be reported at a minimum of 5-year follow-up.
Authors: Alvaro A Martinez; Jose Gonzalez; Hong Ye; Mihai Ghilezan; Sugandh Shetty; Kenneth Kernen; Gary Gustafson; Daniel Krauss; Frank Vicini; Larry Kestin Journal: Int J Radiat Oncol Biol Phys Date: 2011-02-01 Impact factor: 7.038
Authors: Jeff Michalski; Kathryn Winter; Mack Roach; Arnold Markoe; Howard M Sandler; Janice Ryu; Matthew Parliament; James A Purdy; Richard K Valicenti; James D Cox Journal: Int J Radiat Oncol Biol Phys Date: 2012-07-01 Impact factor: 7.038
Authors: Joshua J Morigi; Phillip D Stricker; Pim J van Leeuwen; Reuben Tang; Bao Ho; Quoc Nguyen; George Hruby; Gerald Fogarty; Raj Jagavkar; Andrew Kneebone; Adam Hickey; Stefano Fanti; Lisa Tarlinton; Louise Emmett Journal: J Nucl Med Date: 2015-06-25 Impact factor: 10.057
Authors: Z Fuks; S A Leibel; K E Wallner; C B Begg; W R Fair; L L Anderson; B S Hilaris; W F Whitmore Journal: Int J Radiat Oncol Biol Phys Date: 1991-08 Impact factor: 7.038
Authors: W Robert Lee; James J Dignam; Mahul B Amin; Deborah W Bruner; Daniel Low; Gregory P Swanson; Amit B Shah; David P D'Souza; Jeff M Michalski; Ian S Dayes; Samantha A Seaward; William A Hall; Paul L Nguyen; Thomas M Pisansky; Sergio L Faria; Yuhchyau Chen; Bridget F Koontz; Rebecca Paulus; Howard M Sandler Journal: J Clin Oncol Date: 2016-04-04 Impact factor: 44.544
Authors: Alice Dragomir; Daniela Dinea; Marie Vanhuyse; Fabio L Cury; Armen G Aprikian Journal: BMC Health Serv Res Date: 2014-06-13 Impact factor: 2.655
Authors: Randall J Brenneman; Edward Soffen; Hiram A Gay; Peter F Orio; John P Christodouleas; John C Baumann; Brian C Baumann Journal: Transl Androl Urol Date: 2019-07
Authors: Juanita Crook; Joseph P Rodgers; Thomas M Pisansky; Edouard J Trabulsi; Mahul B Amin; William Bice; Gerard Morton; Albert D Murtha; Eric Vigneault; Joelle Helou; Jeff M Michalski; Mack Roach; David Beyer; Ashesh B Jani; Eric M Horwitz; Adam Raben; Stephanie Pugh; Howard Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2021-11-03 Impact factor: 7.038
Authors: O Pons-Llanas; J Burgos-Burgos; S Roldan-Ortega; A Conde-Moreno; F Celada-Alvarez; J C Ruiz-Martinez; F Lliso-Valverde; A Tormo-Micó; J Perez-Calatayud; J López-Torrecilla Journal: Rep Pract Oncol Radiother Date: 2020-07-05
Authors: Finbar Slevin; Samantha Hodgson; Sree Lakshmi Rodda; Peter Bownes; David Bottomley; Ese Adiotomre; Bashar Al-Qaisieh; Emma Dugdale; Oliver Hulson; Joshua Mason; Jonathan Smith; Ann M Henry Journal: Clin Transl Radiat Oncol Date: 2020-03-27